Mercy Collaborates in Groundbreaking Cancer Detection Study
Mercy is embarking on a pioneering clinical study aimed at assessing the effectiveness of GRAIL's Galleri multi-cancer early detection (MCED) test, specifically among individuals enrolled in Medicare. This initiative promises significant advancements in early cancer detection for a demographic that has faced challenges in accessing innovative health solutions.
The Purpose of the REACH Study
The REACH study is a comprehensive three-year endeavor, designed to compare the outcomes of nearly 50,000 Medicare beneficiaries who undergo an annual Galleri test with those who do not receive this particular screening. This large-scale analysis seeks to establish a clearer understanding of the test's clinical impact on detecting multiple types of cancer at early stages.
Focus on Underrepresented Populations
Enrollment for the study specifically targets Medicare beneficiaries who are traditionally underrepresented in clinical trials. This focus is crucial as it expands the type of data and results, ensuring that the insights gained from the study reflect a diverse population.
Leadership and Commitment
Dr. Damon Broyles, who serves as Mercy's vice president of clinical innovation and the medical director for the MCED initiative, emphasizes the importance of this study. He noted, "Mercy was among the first to offer MCED tests to our patients, and it was essential for us to participate in this landmark study as it propels forward the real-world evidence needed to “extend access to vital cancer screening for Medicare beneficiaries.”
Recognizing the Need for Early Cancer Detection
As age significantly increases the risk of cancer, Medicare beneficiaries often encounter a dire need for early detection methods. Approximately 70% of individuals who succumbed to cancer in recent years were aged 65 and older. With the alarming statistic that more than half of all cancer diagnoses in the U.S. occur in this elderly population, the Galleri test aims to shift the paradigm by identifying potential cancers early when they may be more treatable.
Eligibility Criteria for the Study
For those Medicare beneficiaries aged 50 and above interested in participating in the REACH study, eligibility is likely, which opens the doors for many to access potentially life-saving testing. Participants can seek additional information through Mercy's dedicated channels.
About Mercy
Mercy stands as one of the largest health systems in the United States, recognized for providing excellent patient experiences as rated by NRC Health. Serving millions annually, Mercy is committed to delivering nationally recognized care and operates one of the largest and most efficient Accountable Care Organizations in the nation. With an extensive network comprising 55 acute care and specialty hospitals, numerous outpatient facilities, and over 5,000 medical professionals across several states, Mercy’s impact on health care is monumental. The organization's dedication extends to providing exceptional community benefits, treating patients regardless of their ability to pay, and investing heavily in free care initiatives. In the previous fiscal year alone, Mercy contributed over half a billion dollars to community health and outreach, further highlighting its commitment to serving those in need.
Frequently Asked Questions
What is the main goal of the REACH study?
The main goal is to evaluate the clinical effectiveness of the Galleri multi-cancer early detection test among Medicare beneficiaries.
Who can participate in the study?
Medicare beneficiaries who are at least 50 years old are likely to be eligible for participation.
Why is early cancer detection important?
Early detection significantly increases the chances of successful treatment and recovery from cancer, especially in older populations.
How does the Galleri test work?
The Galleri test detects multiple types of cancers using a simple blood draw, which can indicate the presence of cancer even before symptoms appear.
What is Mercy’s role in this study?
Mercy is actively leading the study to gather real-world evidence on the Galleri test’s effectiveness in screening for cancer, aiming to improve patient outcomes.
